- Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas' newly created Genetic Regulation Primary Focus

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy

- First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors1,2 -

XTANDI is Now FDA-Approved for the Treatment of Metastatic Castration-Sensitive Prostate Cancer in Addition to Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer

Catherine Levitt and Charlotte Stanton named to key global and regional senior roles

Two exciting biotechs win a year of access to life-science incubator and in-house Astellas expertise to advance their early drug discovery research

Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation

- Companies to Initiate Phase 3 Trial to Support Global Registrations -